CD3-CD20 bispecific antibody-based therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD3-CD20 bispecific antibody-based therapy, covering 2025-11-18 to 2025-11-18. Get the full timeline:
Most recent: Clinical Trial Update: A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]